Loading
LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.
LILRB1 (chromosome 19q13.42) is a receptor for class I MHC antigens that recognises a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles and the cytomegalovirus homologue UL18; ligand binding gives inhibitory signals and down-regulates the immune response, and engagement on NK or T cells protects the target from lysis. It is expressed in B cells, monocytes and myeloid, plasmacytoid and tolerogenic dendritic cells, in decidual macrophages and decidual NK cells (protein level) (UniProt Q8NHL6). NGM707, an antibody against LILRB1 and LILRB2, was studied in phase 1/2 with pembrolizumab (NCT04913337); a later phase 2 study was withdrawn by the sponsor (NCT07511972).
In plain words · LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.
LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.
An ITIM-bearing LILR; LILRB receptors negatively regulate myeloid maturation and permit a suppressive myeloid phenotype in tumours (van der Touw et al. 2017).
No product in this corpus aims at LILRB1 (ILT2) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
First described 1997. Earliest sequence paper UniProt cites for the protein: Wagtmann et al, Curr. Biol, 1997, "A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors". Source.
Sources: HGNC HGNC:6605 (approved symbol, name, aliases and cross-references); UniProt Q8NHL6 (protein name, function and tissue specificity)
An ITIM-bearing LILR; LILRB receptors negatively regulate myeloid maturation and permit a suppressive myeloid phenotype in tumours (van der Touw et al. 2017).
Query for this target: (TITLE:"LILRB1" OR ABSTRACT:"LILRB1" OR TITLE:"ILT2" OR ABSTRACT:"ILT2" OR TITLE:"LIR-1" OR ABSTRACT:"LIR-1" OR TITLE:"CD85j" OR ABSTRACT:"CD85j" OR TITLE:"leukocyte immunoglobulin like receptor B1" OR ABSTRACT:"leukocyte immunoglobulin like receptor B1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LILRB1 (ILT2), not a curated reading list.
Shares HLA-A, Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle, Pembrolizumab and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.
Shares Checkpoint (two meanings), The cancer-immunity cycle and the tag checkpoint-map.